Home > News > Arch raises $400 million venture fund
December 10th, 2007
Arch raises $400 million venture fund
Arch Venture Partners, the 21-year-old venture capital firm whose Seattle area investments include Allozyne, Trubion Pharmaceuticals and VLST, has raised a $400 million venture fund.
It is the firm's seventh fund. The money will be invested in early-stage companies in the biotechnology, advanced materials, nanotechnology and semiconductor sectors.
Premier Healthcare Pitch Competition comes to Atlanta this May April 12th, 2014
Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014
Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Metabolon, Inc. April 7th, 2014
Hawk Trade Secures Funding and Development Capital for Nanotec Industries: Nanotec Industries successfully negotiates funding for development of nano-sized treatment and imaging delivery device facility through Hawk Trade April 3rd, 2014
UT Arlington physicist creates new nanoparticle for cancer therapy April 16th, 2014
Relieving electric vehicle range anxiety with improved batteries: Lithium-sulfur batteries last longer with nanomaterial-packed cathode April 16th, 2014
Aerotech X-Y ball-screw stage for economical high performance Planar positioning April 16th, 2014
Energy Research Facility Construction Project at Brookhaven Lab Wins U.S. Energy Secretary's Achievement Award April 16th, 2014